Two studies of HPV vaccine effectiveness against condyloma were recently published (JNCI March 2013, JAMA January 2014). Strong protective effects (93%) of quadrivalent HPV vaccination against condyloma was shown for girls vaccinated before age 14, and 3 doses of the vaccine (taken at 0, 2 and 6 months) proved to be more effective than two doses (taken at 0 and 2 months). Currently one study on quadrivalent vaccine effectiveness against CIN2+ in Sweden is performed and another study on dose effectiveness against CIN2+ in a Danish-Swedish collaboration.
Safety follow-up of HPV vaccination in the Swedish and Danish population
The aim of this study was to provide an early surveillance of serious adverse events following HPV vaccination in Sweden and Denmark among women who were vaccinated between 2006 and 2010. The study took advantage of the unique Nordic population-based health care databases and was performed in collaboration with Statens Serum Institut in Denmark. No evidence supporting an association between HPV vaccination and autoimmune, neurological, and thromboembolic adverse events could be found (BMJ, 2013).
Socio-economic determinants of HPV vaccination among girls and young women in Sweden
A national study to investigate the association between socio-economic status and HPV vaccination uptake in school based and catch-up vaccination will be undertaken, where the impact of education, income and geographical location of vaccinees and their parents is assessed.